Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Gross Profit: 2022-2025

Historic Gross Profit for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $10.6 million.

  • Stoke Therapeutics' Gross Profit rose 117.25% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.6 million, marking a year-over-year increase of 1128.17%. This contributed to the annual value of $36.6 million for FY2024, which is 316.34% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Gross Profit is $10.6 million, which was down 23.05% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Gross Profit ranged from a high of $158.6 million in Q1 2025 and a low of $2.5 million during Q2 2023.
  • In the last 3 years, Stoke Therapeutics' Gross Profit had a median value of $4.9 million in 2024 and averaged $21.2 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Gross Profit fell by 23.21% in 2023, and later soared by 3,661.12% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Gross Profit (Quarterly) stood at $3.3 million in 2022, then fell by 14.26% to $2.8 million in 2023, then skyrocketed by 707.07% to $22.6 million in 2024, then surged by 117.25% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in Q3 2025, $13.8 million for Q2 2025, and $158.6 million during Q1 2025.